Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415

Author:

Khairnar Rahul1ORCID,DeMora Lyudmila2,Sandler Howard M.3ORCID,Lee W. Robert4,Villalonga-Olives Ester1ORCID,Mullins C. Daniel1ORCID,Palumbo Francis B.1ORCID,Bruner Deborah W.5ORCID,Shaya Fadia T.1,Bentzen Soren M.6ORCID,Shah Amit B.7,Malone Shawn8ORCID,Michalski Jeff M.9ORCID,Dayes Ian S.10ORCID,Seaward Samantha A.11ORCID,Albert Michele12,Currey Adam D.13,Pisansky Thomas M.14,Chen Yuhchyau15,Horwitz Eric M.16ORCID,DeNittis Albert S.17,Feng Felix18,Mishra Mark V.19

Affiliation:

1. Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD

2. NRG Oncology Statistics and Data Management Center, Philadelphia, PA

3. Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA

4. Department of Radiation Oncology, Duke University, Durham, NC

5. Department of Radiation Oncology, Emory University, Atlanta, GA

6. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD

7. WellSpan Health-York Cancer Center, York, PA

8. Ottawa Hospital and Cancer Center, Ottawa, Ontario, Canada

9. Department of Radiation Oncology, Washington University, St Louis, MO

10. Juravinski Cancer Center at Hamilton Health Sciences, Hamilton, Ontario, Canada

11. Kaiser Permanente Northern California, Oakland, CA

12. Saint Anne's Hospital, Fall River, MA

13. Zablocki VAMC and the Medical College of Wisconsin, Milwaukee, WI

14. Department of Radiation Oncology, Mayo Clinic Rochester, Rochester, MN

15. Department of Radiation Oncology, University of Rochester, Rochester, NY

16. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA

17. Department of Radiation Oncology, Main Line Health, Wynnewood, PA

18. Department of Radiation Oncology, University of California San Francisco, San Francisco, CA

19. Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD

Abstract

PURPOSE To compare the predictive ability of mapping algorithms derived using cross-sectional and longitudinal data. METHODS This methodological assessment used data from a randomized controlled noninferiority trial of patients with low-risk prostate cancer, conducted by NRG Oncology (ClinicalTrials.gov identifier: NCT00331773 ), which examined the efficacy of conventional schedule versus hypofractionated radiation therapy (three-dimensional conformal external beam radiation therapy/IMRT). Health-related quality-of-life data were collected using the Expanded Prostate Cancer Index Composite (EPIC), and health utilities were obtained using EuroQOL-5D-3L (EQ-5D) at baseline and 6, 12, 24, and 60 months postintervention. Mapping algorithms were estimated using ordinary least squares regression models through five-fold cross-validation in baseline cross-sectional data and combined longitudinal data from all assessment periods; random effects specifications were also estimated in longitudinal data. Predictive performance was compared using root mean square error. Longitudinal predictive ability of models obtained using baseline data was examined using mean absolute differences in the reported and predicted utilities. RESULTS A total of 267 (and 199) patients in the estimation sample had complete EQ-5D and EPIC domain (and subdomain) data at baseline and at all subsequent assessments. Ordinary least squares models using combined data showed better predictive ability (lowest root mean square error) in the validation phase for algorithms with EPIC domain/subdomain data alone, whereas models using baseline data outperformed other specifications in the validation phase when patient covariates were also modeled. The mean absolute differences were lower for models using EPIC subdomain data compared with EPIC domain data and generally decreased as the time of assessment increased. CONCLUSION Overall, mapping algorithms obtained using baseline cross-sectional data showed the best predictive performance. Furthermore, these models demonstrated satisfactory longitudinal predictive ability.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3